Aarti Drugs Q2 FY27 Revenue ₹828.8 Cr, PAT ₹82.8 Cr
Aarti Drugs Limited announced its unaudited financial results for the Quarter and Half Year ended September 30, 2026. For Q2 FY27, total revenue stood at ₹828.8 crore, a 27% YoY increase from ₹652.9 crore in Q2 FY26. EBITDA grew by 63% YoY to ₹137.9 crore, with EBITDA margin expanding by 370 bps to 16.6%. Profit After Tax (PAT) surged by 83% YoY to ₹82.8 crore, and PAT margin improved by 310 bps to 10.0%. For H1 FY27, revenue was ₹1,532.4 crore (up 23% YoY), EBITDA was ₹234.8 crore (up 48% YoY), and PAT was ₹132.9 crore (up 34% YoY). The Specialty Chemicals business nearly doubled, and the Formulations business grew 58% YoY. The company also announced a management transition with Mr. Prakash M. Patil retiring and Mr. Rashesh Gogri taking over as Chairman.
Key Highlights
- Q2 FY27 revenue increased 27% YoY to ₹828.8 crore.
- EBITDA grew 63% YoY to ₹137.9 crore with margin expansion.
- PAT surged 83% YoY to ₹82.8 crore, margin improved significantly.
- Specialty Chemicals and Formulations businesses showed strong growth.
- Management transition announced with new Chairman appointment.
Price Impact
More from AARTIDRUGS